Yale taps Genesis CRO for drug discovery services

By Maggie Lynch

- Last updated on GMT

(Image: Getty/f11photo)
(Image: Getty/f11photo)

Related tags CRO Drug discovery Research and development Research

Yale University is partnering with CROs to provide drug discovery services to awardees of the Blavatnik Fund for Innovation – which aims to bridge the gap between early-stage research and product development.

The new partnership will bring Genesis Biotechnology Group (GBG) and its contract research organization (CRO) arm, Genesis Drug Discovery & Development (GD3), together with Yale to provide drug discovery services to researchers at the university.

GD3’s service providers include PharmOptima – after an acquisition​ in 2017 – Invivotek, and Venenum Biodesign.

According to William Wiesler, director of new ventures at the office of cooperative research at Yale University, the $25m Blavatnik Fund for Innovation was designed to bridge the gap from life science research to business. The fund will invest up to $300,000 per project to conduct experiments that prospective industry partners view as critical.

“It is the intent of the fund that most of the work be done outside of Yale at highly regarded CRO’s that are trusted by pharmaceutical companies and biotech investors. Genesis Biotech Group was chosen as Yale’s newest partner to provide these services on the basis of their strong reputation, breadth of services, and high-quality engagement with Yale Faculty,” ​said Wiesler.

Yale faculty will be able to, therefore, explore ideas with members of the Genesis Biotech group to develop research plans in collaboration, explained Wiesler.

He also stated that Yale labs have had a number of breakthrough medical products receive approval.

“Yale’s pharmaceutical pipeline boasts five marketed drugs and 20 in clinical development,” ​said Weisler. Partnerships, like that of GBG, are expected to grow the pipeline and advance more projects through preclinical development into trials. 

Related news

Show more

Related products

show more

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Content provided by Elligo Health Research® | 13-Apr-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more